MMP-3 is an outstanding serological marker that can identify patients with high risk of developing bone erosions in the near future even in an early phase of the disease.

Furthermore, due to its direct implication in the joint destruction process, MMP-3 can also be used to monitor disease activity and therapy success, thereby helping physicians to create and adapt an individualized drug therapy for each patient.

After 10 years working in the autoimmunity field with headquarters in Germany and a subsidiary in the eastern USA, AESKU opens a new office in San Francisco (Oakland, California), to increase our presence and support in America.

Today the combination of most reliable results and the best possible workflow is amongst the most important requirements in any clinical laboratories because time schedules in laboratories are getting more and more tighter all around the world.

AESKU.Diagnostics GmbH & Co. KG, as a leading diagnostic company in the autoimmunity market, has been awarded with the STEP Award 2010.

Offering the most extensive product panel, AESKU provides a comprehensive platform for autoimmune disease testing. AESKU was selected for its strategically aligned and long-term funding concept.

AESKU.Systems received a honorable mention during the award ceremony of the Innovation Prize 2010 hosted in Kaiserslautern by the minister of economic affairs of the German federal state Rhineland-Palatinate.

AESKU.Diagnostics is now offering a complete autoimmune Diabetes panel allowing simultaneous determination of IA2-GAD65 Screen, IA2, GAD65 and anti-insulin.

The AESKULISA^® New generation tTG and the Deamidated gliadin peptides (DGP) are now available with the following immunoglobulins: IgG, IgA, Check (IgG/IgA mixed conjugate) and GA (IgG+IgA independent conjugates provided within the same kit).

AESKU.AWARD 2010 goes to three outstanding researchers and a real patient advocate in autoimmunity

On May 6, 2010, Aesku.Diagnostics´ “Aesku.Award for life contribution to autoimmunity” was already awarded for the fourth time.

AESKU.DIAGNOSTICS is glad to announce the launch of our new Deamidated Gliadin peptides (DGP) ELISA line to complete our Celiac disease product offer.